Background/Aims: Emerging studies on brain-derived neurotrophic factor (BDNF) have shown that might be novel biomarkers and therapeutic targets for cancer. We explore the role of BDNF in the tumorigenesis of bladder cancer and the underlying molecular mechanism. Methods: 368 patients with diagnosed bladder cancer and 352 healthy controls were enrolled to evaluate the association of BDNF and the miR-146b. Bioinformatics algorithm analysis and luciferase assay were performed to identify the target genes of miR-146b. Real-time PCR and western-blot were carried out to validate the relationship between miR-146b and CRK. MTT assay and FACS were used to evaluated the proliferation and apoptosis of cancer cells. MVs were isolated and transfect into the culture cells to confirm the above observation.
Introduction
As the 2 nd most common urological malignancy, bladder cancer contributes to 5% of deaths related to cancer and is responsible for healthcare costs as much as $4 billion worldwide [1] . Men are four times more likely to develop the disease than women. The incidence in white men is twice higher than that in black men. Urothelial cell carcinoma (UCC) is the most common type, contributing to 90% of bladder cancers [2] . As natural biomaterials, micro-vehicles (MVs) seem to function as a carrier to transport bioactive molecules to target cells [3] . In addition, MVs can deliver oncolytic adenovirus or chemotherapeutic agents to tumor cells [4] . Interestingly, MVs themselves can also act as messengers to activate signaling pathways. It has been demonstrated that pre-instillation of MVs as natural biomaterials significantly increases the suppressant efficacy of intra-vesical chemotherapy on development and hematuria onset of orthotropic bladder cancer in mice, and MVs may function as an effective sensitizer for facilitating non-muscle-invasive bladder cancer (NMIBC) chemotherapy with unique clinical benefits [5] .
MicroRNAs (miRNAs) plays a key role in posttranscriptional negative regulators in mRNA expression of the target genes [6] . A growing evidence has demonstrated that biological processes including tumor invasion pathways, Epithelial-mesenchymal transition (EMT), apoptosis avoidance, cell proliferation, organ development and angiogenic signaling are modulated by a variety of microRNAs [7] . Deregulated expression of miRNA has been observed in a variety of human tumors such as bladder tumor, and much proven data have revealed that some specific microRNAs could act as tumor suppressor genes or oncogenes [8] . Moreover, the first study of variant miRNA expression in bladder tumor presented in 2007 and found that upregulated urinary miRNAs and 10 miRNAs have been demonstrated to be clinically beneficial for diagnostics of noninvasive bladder cancer [9, 10] . It has been shown that, following RNase treatment, MVs lost their transforming abilities revealing that RNAs in MVs accounts for, at least partially, the transformation to the malignancy [11] . It has been shown miR-146b-5p functioned as a critical regulator of NUMB and other genes to increase the transformation, and also triggered cell proliferation and genomic instability of the recipient cells, which will give significant insights into the leukemogenesis, and miR146b-5p within BCR-ABL1-positive MVs enhances leukemic transformation of hematopoietic cells [12] .
Earlier reports demonstrated that overexpression of CRK in a variety of invasive cancers is related to tumor progression [13] . It has been demonstrated that CRK is a promising target at molecule level in aggressive bladder cancer on the basis of data from the present study [14] . Actually, CRK was upregulated in bladder cancer tissue specimens when compared with normal urothelium [14] . Simultaneous knockdown of CRK inhibited cell invasiveness, migration and proliferation, via a compromised HGF/c-Met feedback loop in two independent invasive bladder cancer cell lines [14] .
One variant of BDNF has been reported to alter the enzymatic activity of the host gene, and over-expression of BDNF has been found to be associated with the tumorigenesis of bladder cancer [15, 16] . It has also been shown that BDNF could promote the expression of miR-146 [17] . Using computational analysis, we found the CRK is a potential target gene of miR-146b, and CRK could facilitate the phosphorylation of AKT, which is an oncogene in bladder cancer [14] . Here, we isolated the MVs from human Wharton's jelly mesenchymal stem cells (hWJMSCs) from human umbilical cord, which has been reported to suppress the proliferation of bladder cancer cells, and examined the effect of the variant in BDNF on the expression of miR146b and its suppressive effect on the proliferation of bladder cancer cells [18] .
in Table 1 . 5 ml of peripheral blood were collected from each participant after written consent was provided, and Ethics Committee of the Hospital of our institution has approved the protocol of the study.
Human umbilical cord collection
Human umbilical cord tissues were collected from 10 full-term healthy pregnant women from our institute. All of the samples were stored in liquid nitrogen. Cellular isolation was started within 4 hour after partum. Ethics Committee of the Hospital of our institution has approved the protocol of the study and written informed consents were obtained from all participants prior to the study. The patients have already signed informed consent for participation in the study.
The hWJMSCs isolation
Cold Dulbecco's modified Eagle medium (DMEM) was utilized to store umbilical cords aseptically, and cellular isolation was began within 4 hour after partum. Firstly, removed blood cells from the vein and arteries, pulverized the umbilical cord into 1-2 mm 3 pieces approximately. Petri dish with DMEM supplemented with low glucose (DMED-LG, Gibco) and 10% fetal bovine serum (FBS, Gibco) was utilized to maintain the cord pieces under an atmosphere with 5% CO 2 at 37°C Then the fresh medium was replaced the old medium every two days. 0.25% trypsin (Gibco) was utilized to collect the adherent cells after two weeks. Only cells between passage 3 and 6 were used for research. Three independent experiments were carried out.
Isolation of MVs
Briefly, DMEM contained 0.5% BSA (bovine serum albumin) (Sigma-Aldrich, St. Louis, MO) and deprived of FBS was utilized to incubate hWJMSCs for 12 hours. RPMI-1640 with 0.5% BSA and without serum was utilized to maintain HFFs. Trypan blue exclusion was utilized to detect viability of hWJMSCs (99%) and HHFs (90%), and TUNEL assay was performed to detect apoptosis of hWJMSCs (0%) and HHFs (3%). Then the cells were subjected to centrifugation for 20 minutes at 2, 000 g for decontamination, next the cell-free supernatants were subjected to ultracentrifuge at 4°C for 60 min at 100, 000 g in a SW41 swing rotor (Beckman Coulter Optima L-80K ultracentrifuge; Beckman Coulter, Fullerton, CA). Serum-free M199 (Sigma-Aldrich) supplemented with 25 mM HEPES was utilized to wash the MVs, then subjected to ultracentrifuge at 4°C for 60 min at 100, 000 g. Serum-free M199 (Sigma-Aldrich) was utilized to suspend MV pellets, and Bradford assay (Bradford protein assay kit, P0006, beyotime institute of biotechnology) was utilized to quantify protein content. Limulus test (Charles River Laboratories, Inc., Wilmington, MA, USA) was utilized to exclude Endotoxin contaminations of MVs following supplier's recommendation. Three independent experiments were carried out.
Taqman
The TaqMan methodology (AB, foster city, CA) was utilized to analyze the genotype of the SNP (BDNF VAL66MET) based on the instructions of the supplier.
MiRNA isolation and real-time PCR
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was utilized to extract total RNA following standard protocol indicated by manufacturer. Bio Photometer plus (Eppendorf AG, Hamburger, Germany) was utilized to check the quality and quantify RNA extracted. For detection of CRK, ReverTra Ace qPCR RT Kit (TOYOBO, Osaka, Japan) was utilized to synthesize cDNA with 1 mg total RNA. In order to detect miR- Cell culture and transfection RPMI 1640 medium (GIBCO®, Life Technologies, Carlsbad, CA, USA) contained 100 mg/mL ampicillin and 10% FBS (fetal bovine serum) was utilized to maintain the T24 AND RT4 cells in an incubator with 5% CO 2 at 3°C. Lipofectamine 2000 (Invitrogen, USA) was utilized to transfect the cells with MVs of different genotype, miR-146b mimic, CRK at a final concentration of 50 nM. All tests were performed three times.
Cell proliferation T24 and RT4 cells were cultured into 48-well plates at a final concentration of 2.5×10 3 cell/well, after the cells attached for 6 hours, RPMI1640 medium was utilized to replace the medium, and incubated for 72 hours. CCK-8assay kit (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was utilized to determine cell proliferation 48 hours after transfection based on supplier's guideline. Synergy™ 2 MultiMode Microplate Reader (BioTek Instruments, Inc., headquartered in Winooski, VT, USA) was utilized to determine absorbance value (A) at 450 nm. All experiments were performed three times.
Luciferase assay and Vector construction (miR-146b promoter+BDNF)
Briefly, PCR was carried out to amplify full promoter region of miR-146b from DNA templates isolated from samples that collected from subjects. BDNF coding sequence contained VAL/VAL was amplified. Then the PCR products were sub-cloned into pGL3-basic vector (Promega, MD, USA). A firefly gene, as reporter, was inserted into the downstream of miR-146b promoter. In the vector containing BDNF VAL/VAL, site-directed mutagenesis kit was used to introduce the VAL66MET polymorphism, with one vector containing BDNF VAL/VAL and the other vector containing BDNF MET/MET. The Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was utilized to transfect the cells with BDNF (VAL/VAL or MET/MET) or the vector containing the promoter of miR-146b following manufacturer's recommendation. 48 hours after transfection, A Beckman Coulter LD400 luminometer (Beckman, Fullerton, CA) and Dual-Glo substrate system (Promega, Madison, WI, USA) were utilized to measure luciferase activity 48 hours after transfection. Experimental data was shown as the ratio of Renilla luciferase/ Firefly luciferase. Each test was carried out three times.
Luciferase assay and Vector construction (miR-146b and target 3UTR)
The whole sequence of CRK 3'UTR with miR-146b binding sites was amplified using PCR, and the full fragment CRK 3'UTR was sub-cloned into psi-CHECK2 luciferase reporter vector (Promega, Madison, WI, USA) downstream of firefly luciferase, and site-directed mutagenesis kit was used to generate CRK-3'UTR and CRK-Mut-3'UTR respectively. Then the cells were co-transfected with miR-146b mimic/NC (negative control) and reporter constructs containing either wild-type or mutant CRK 3'UTR by lipofectamine 2000 (Invitrogen, CA, USA) following manufacturer's recommendation. 48 hours after transfection, A Beckman Coulter LD400 luminometer (Beckman, Fullerton, CA) and Dual-Glo substrate system (Promega, Madison, WI, USA) were utilized to measure luciferase activity 48 hours after transfection. Experimental data was shown as the ratio of Renilla luciferase/ Firefly luciferase. Each test was carried out three times.
Western blot analysis
Lysis buffer contained 150 mM NaCl, 1 mM EDTA, 50 mM Tris (pH 8) 0.25% sodium deoxycholate, 0.1%Triton X-100 and protease inhibitor cocktail (Roche, Rotkreuz, Switzerland) was utilized to extract whole cells protein for western-blot analysis. 10% SDS-PAGE was utilized to resolve protein samples, and then the gels electro-transferred onto a nitrocellulose membranes (GE Healthcare, Little Chalfont, UK), and 5% non-fat milk was utilized to block the membrane at room temperature for 60 min, and primary antibodies against CRK at a dilution of 1:2000 (Sigma-Aldrich, St. Louis, MO, USA), primary antibodies Against AKT at a dilution of 1:1000 (Sigma-Aldrich, St. Louis, MO, USA), primary antibody against p-AKT at a Cell apoptosis FITC Annexin V Apoptosis Detection Kit contained PI (Bio Legend, San Diego, CA) was utilized to perform cell apoptosis assay. Cold Cell Staining Buffer (Bio Legend, San Diego, CA) was utilized to wash the cells twice, Annexin V Binding Buffer (Bio Legend, San Diego, CA) was utilized to re-suspend the cells at a final concentration of 5×10 6 cells per well, 10 μL propidiumiodide and 5 μL of FITC Annexin V (Biolegend, San Diego, CA) was utilized to stain the cells, and incubated at room temperature for 15 min in darkness. FACSCalibur flow cytometer (BD Biosciences, New Jersey, USA) were utilized to evaluate the apoptosis of T24 AND RT4 cells. Three independent experiments were carried out.
Statistical analysis SPSS version 17.0 (SPSS, Chicago, IL, USA), GraphPad Prism software (GraphPad, La Jolla, CA, USA) and Microsoft excel (Microsoft Corporation., Redmond, Washington, US) were utilized to perform all statistical analysis. Kruskal-Wallis test, Mann-Whitney U test and Student's t-test was utilized to calculate obvious differences among independent groups. The value of P less than 0.05 was considered statistically significant.
Results

BDNF Val66Met polymorphism is associated with the risk of bladder cancer
To study the association between the BDNF Val66Met polymorphism and the risk of bladder cancer, 368 patients with diagnosed bladder cancer and 352 controls were enrolled in this study, and the demographic parameters were comparable between the case and control groups, as shown in Table 1 . Furthermore, the genotypic and allelic frequencies of BDNF Val66Met polymorphism were determined and compared between the case and control groups. Comparing with Val/Val and Val/Met, Met/Met was significantly associated with the risk of bladder cancer (as shown in Table 2 ).
The BDNF Val66Met polymorphism regulates the transcription activity of miR-164b
The effect of BDNF Val66Met polymorphism upon the transcription activity of the miR-146b promoter was examined using luciferase assay. In Fig.  1A , we showed the variant located in the coding region of BDNF, and it possible effect on the promoter of miR-146b. We 
CRK is a virtual target gene of miR-146b
Bioinformatics algorithm analysis was performed to explore the target gene of miR-146b. As shown in Fig. 2 , CRK, IGFBP5, RASGRP1 and THFAIP8 were identified as miR146b target genes with binding sites located in 3'UTR. In addition, we found that luciferase activity of wild-type CRK 3'UTR was apparently reduced subsequent to transfection with miR-146b compared to that in control, but the luciferase activity of mutant CRK 3'UTR and control showed no obvious difference ( Fig. 2A) . As shown in Fig. 2B , miR-146b might also target IGFBP5 through bind IGFBP5 3'UTR, whereas the luciferase activity of wild-type and mutant IGFBP5 3'UTR was comparable with control following introduction of miR-146b. Similarly, RASGRP1 was identified as a protential miR-146b target gene with a binding site located within 3'UTR of CRK, but the luciferase activities of wild-type and mutant RASGRP1 3'UTR were similar with control after transfection with miR146b (Fig. 2C) . MiR-146b might bind THFAIP8 3'UTR and regulate it expression, while luciferase activities of wild-type and mutant THFAIP8 3'UTR were similar with control after transfection with miR-146b (Fig. 2D) . These results indicated that CRK is a virtual target gene of miR-146b with a binding site located within CRK 3'UTR. 2 . A: MiR-146b might target CRK through bind to CRK 3'UTR, and miR-146b significantly suppressed luciferase activity of wild-type CRK 3'UTR, but not that of mutant CRK 3'UTR. B: MiR-146b might target IGFBP5 via binding to IGFBP5 3'UTR, and miR-146b didn't affect luciferase activity of wild-type and mutant IGFBP53'UTR. C: MiR-146b might target RASGRP1 via binding to RASGRP1 3'UTR, and miR-146b didn't affect luciferase activity of wild-type and mutant RASGRP1 3'UTR. D: MiR-146b might target THFAIP8 through bind to THFAIP8 3'UTR, and miR-146b didn't affect luciferase activity of wild-type and mutant THFAIP8 3'UTR (Fig. 3A) . However, the expression of IGFBP5 (Fig. 3B) MiR-146b had no effect on levels of IGFBP5, p-AKT and AKT in T24 and RT4 cells. C: MiR-146b had no effect on levels of RASGRP1, p-AKT and AKT in T24 and RT4 cells. D: MiR-146b had no effect on levels of THFAIP8, p-AKT and AKT in T24 and RT4 cells : miR-146b had no effect on the levels of IGFBP5, p-AKT and AKT in T24 and RT4 cells. (C): miR-146b had no effect on the levels of RASGRP1, p-AKT and AKT in T24 and RT4 cells. (D): miR-146b had no effect on the levels of TNFAIP8, p-AKT and AKT in T24 and RT4 cells. ( Fig. 4B) Fig. 5 , MV-BDNF Val/ Val-miR-146b (Fig. 5A) or MV-BDNF Val/ Met-miR-146b (Fig. 5B) significantly suppressed growth rate of T24 and RT4 cells compared to those of NC group, but treating with CRK attenu- (Fig. 5C) . Meanwhile, MV-BDNF Val/Val-miR-146b (Fig. 6A) or MV-BDNF Val/Met-miR-146b (Fig. 6B ) significantly promoted survival of T24 and RT4 cells compared with those of NC group, but treating with CRK attenuated the promotion effect of MV-BDNF Val/ValmiR-146b (Fig. 6A) or MV-BDNF Val/MetmiR-146b (Fig. 6B ) in T24 and RT4 cells, while cells treated with MV-BDNF Met/ Met-miR-146b or MV-BDNF Met/Met-miR146b+CRK exhibited a comparable growth rate of T24 and RT4 with NC group (Fig. 6C ).
MVs collected from individuals of different genotypes regulates the activation of AKT, but not the expression of AKT
To further explore the mechanism underlying, the protein and phosphorylation levels of AKT were determined in the culture cells treated with MVs of different genotype. As shown in Fig. 7 , the protein expression of AKT was all comparable among all differently treated group as well as the control group. While the introduction of miR-146b carried by MVs collected from individuals of Val/Val or Val/Met substantially suppressed the activation level of AKT, but the MVs genotyped as Met/Met had minimal effect on the activation level of AKT.
Discussion
As plasma membrane-derived particles, MVs are produced from cells through plasma membrane's outward budding and fission [19] . MVs have fundamental pathological / physiological roles, such as the advancement of the tumor through the regulation of tumor metastasis, angiogenesis, immune inhibition and tumor-stroma interactions [20] . Tumor cells fundamentally release MVs when they transmit their metastasis-related proteases, receptors of membrane growth factor and other molecules with bioactivity to other tissue components, nontumor cells and other tumor cells in the tumor microenvironment, hence enhancing tumor progression [21] . It has been shown that MVs shedding is a main pathway for secretion of a metastasis-related protease known as cathepsin B, which is released from tumor cells [22] . Studies with human and murine lung cancer cells have demonstrated that the expression of several pro-angiopoietic factors are induced by MVs shed by tumor cells in stromal cells, hence playing an active regulatory role in the behavior of tumor stroma and endothelium [22] . Tumor-derived MVs are abundant in proteases correlated with metastasis, including matrix metalloproteinase (MMP)-2 and MMP-9, which are associated with the degradation of extracellular matrix in the tumor microenvironment, Hence enhancing tumor metastasis [23] . The number of MVs shed by tumor cells have been shown to be related to the invasive ability of tumor cells either in vivo or in vitro [24] . In more recent study, miRNAs have been reported to be involved in cancer occurrence and progression, functioning either as tumor oncogenes or suppressors [25] . Intriguingly, recent reports have shown an association between cancer pathogenesis and miRNA expression for an array of cancer [26] . In bladder tumors or in other cancers, deregulation of a wide range of miRNAs (miR-146b, miR-182, miR-200b and miR-204, miR-145, miR-143, miR-138, miR133b, miR-133a, miR-9, miR-1 ) has been previously observed [27, 28] . And deregulation of miR-146b was considered to be specific in bladder cancer [27] . Using computational analysis and luciferase assay, we screened several possible candidate target genes of miR-146b, and identified CRK as a direct target of miR-146b.
BDNF gene, causing replacement of a valine by a methionine (Val66Met), results in interrupted delivery of either the protein or mRNA to terminals of neuron and decreased release of BDNF protein dependent on activity either in vivo or in vitro [29] . Val66Met SNP is a human-specific frequent genetic variant [30] . Val66Met SNP has been related to decreased volume of prefrontal and hippocampal cortical gray matter and changed performance in memory tasks [31] . Studies in vitro neuronal cultures have demonstrated an effect of BDNF in regulation of miRNA levels, indicating that the functions of natural variant at the BDNF locus may be triggered via alterations in miRNA levels [32] . Val66Met impacts the levels of miRNAs more likely through regulating BDNF-dependent transcription factor binding in regulatory regions rather than through miRNA biogenesis [33] . Among the influenced miRNAs, miR146b and its regulated downstream targets, which are especially rich in neuronal genes, seem to have significant attribution to the biological properties of the Val66Met variant, and lowered levels of miR-146b, resulted in elevated Irak1 protein levels and higher Per1 and Npas4 mRNA levels in vitro and are related to similar alterations in the hippocampus of hBDNF Met/Met mice [17] . In line with this, we performed the luciferase assay to test the effect of BDNF of different genotypes on the transcription of miR-146b promoter, and found that homogenous Met allele significantly undermined the transcription of miR-146b promoter. Furthermore, we collected MVs from individuals of different genotypes, and found that Val/ Val and Val/Met were comparable with each other, and both were substantially higher than that of Met/Met.
The signaling adaptor protein CRK was primarily separated from an avian sarcoma CT10 retrovirus as an oncogene fusion product [34] . Its homologs in mammalian are consisted of CRK-I, CRK-II, and CRK-L (CRK-like). CRK-II has an additional SH3 domain while CRK-I has an SH2 and an SH3 domain. Increased concentrations of CRK mRNAs and the protein are related to the possibility of malignancy of a variety of tumors in human, such as breast tumors, glioblastoma, synovial sarcoma and ovarian tumors [13] . CRK facilitates EMT and is necessary for cell spreading mediated by HGF in epithelial cells of kidney [35] . Previously, we have demonstrated that CRK is necessary for persistent phosphorylation of the SH2 domain binding protein Gab1 responding to HGF stimulation, and the subsequent downstream Rac1 activation in synovial sarcoma cells [36] . These reports indicate that CRK has the possibility to regulate EMT via growth factors such as HGF. It has been demonstrated that the PI3K-AKT pathway acts as an important mediator of CRK-triggered oncogenesis. It is well demonstrated that the stimulation of the AKT pathway offers a survival signal in a lot of circumstances including inhibition of apoptosis, attachment to the extracellular matrix and growth factor stimulation [37] . Hence, it is plausible that CRK enhances anchorage-independent growth by producing a survival signal via the underlying stimulation of the AKT pathway [12] . In this study, we transfected the bladder cancer cells with those MVs collected from the individuals genotyped as Val/Val, Val/Met and Met/Met, and detected miR-146b, CRK mRNA and protein, p-AKT levels among above three groups, and found that Val/Val group showed a higher level of miR-146b, while CRK and p-AKT levels were remarkably repressed after transfecting with MV-BDNF Val/Val-miR-146b or MV-BDNF Val/Met-miR-146b, while notably up-regulated subsequent to transfect with MV-BDNF Val/Met-miR-146b. 
Conclusion
In summary, our results demonstrate the BDNF val66met polymorphism is associated with risk of bladder cancer. In our study, we validated that BDNF Val66Met Polymorphism is significantly influenced the miR-146b levels in MVs, and then its direct target gene CRK. As CRK is an Key kinase influencing the phosphorylation of AKT, BDNF Val66Met Polymorphism regulates the apoptosis and proliferation of bladder cancer cells via miR146b and CRK-AKT pathway.
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